Huai-Hsuan Tseng1, Jeremy J Watts1,2, Michael Kiang1,3, Ivonne Suridjan1, Alan A Wilson1,4,3, Sylvain Houle1,4,3, Pablo M Rusjan1,4,3, Romina Mizrahi1,2,4,3. 1. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada. 2. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 3. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 4. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Abstract
Background: Striatal dopamine (DA) synthesis capacity and release are elevated in schizophrenia (SCZ) and its putative prodrome, the clinical high risk (CHR) state. Striatal DA function results from the activity of midbrain DA neurons projecting mainly from the substantia nigra (SN). Elevated stress-induced DA release in SCZ and CHR was observed in the striatum; however, whether it is also elevated in the SN is unclear. The current study aims to determine whether nigral DA release in response to a validated stress task is altered in CHR and in antipsychotic-naïve SCZ. Further, we explore how DA release in the SN and striatum might be related. Methods: 24 CHR subjects, 9 antipsychotic-naïve SCZ and 25 healthy volunteers (HV) underwent 2 positron emission tomography (PET) scans using the DA D2/3 agonist radiotracer, [11C]-(+)-PHNO, which allows simultaneous investigations of DA in the SN and striatum. Psychosocial stress-induced DA release was estimated as the percentage differences in BPND (%[11C]-(+)-PHNO displacement) between stress and sensory-motor control sessions. Results: We observed a significant diagnostic group by session interaction, such that SCZ exhibited greater stress-induced [11C]-(+)-PHNO % displacement (25.90% ± 32.2%; mean ± SD), as compared to HVs (-10.94% ± 27.1%). Displacement in CHRs (-1.13% ± 32.2%) did not differ significantly from either HV or SCZ. Conclusion: Our findings suggest that elevated nigral DA responsiveness to stress is observed in antipsychotic-naïve SCZ.
Background: Striatal dopamine (DA) synthesis capacity and release are elevated in schizophrenia (SCZ) and its putative prodrome, the clinical high risk (CHR) state. Striatal DA function results from the activity of midbrain DA neurons projecting mainly from the substantia nigra (SN). Elevated stress-induced DA release in SCZ and CHR was observed in the striatum; however, whether it is also elevated in the SN is unclear. The current study aims to determine whether nigral DA release in response to a validated stress task is altered in CHR and in antipsychotic-naïve SCZ. Further, we explore how DA release in the SN and striatum might be related. Methods: 24 CHR subjects, 9 antipsychotic-naïve SCZ and 25 healthy volunteers (HV) underwent 2 positron emission tomography (PET) scans using the DA D2/3 agonist radiotracer, [11C]-(+)-PHNO, which allows simultaneous investigations of DA in the SN and striatum. Psychosocial stress-induced DA release was estimated as the percentage differences in BPND (%[11C]-(+)-PHNO displacement) between stress and sensory-motor control sessions. Results: We observed a significant diagnostic group by session interaction, such that SCZ exhibited greater stress-induced [11C]-(+)-PHNO % displacement (25.90% ± 32.2%; mean ± SD), as compared to HVs (-10.94% ± 27.1%). Displacement in CHRs (-1.13% ± 32.2%) did not differ significantly from either HV or SCZ. Conclusion: Our findings suggest that elevated nigral DA responsiveness to stress is observed in antipsychotic-naïve SCZ.
Authors: Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish Journal: J Neurosci Date: 2012-01-25 Impact factor: 6.167
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga Journal: Acta Psychiatr Scand Date: 1988-08 Impact factor: 6.392
Authors: Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson Journal: Biol Psychiatry Date: 2011-11-30 Impact factor: 13.382
Authors: Nathalie Ginovart; Matthaeus Willeit; Pablo Rusjan; Ariel Graff; Peter M Bloomfield; Sylvain Houle; Shitij Kapur; Alan A Wilson Journal: J Cereb Blood Flow Metab Date: 2006-10-11 Impact factor: 6.200
Authors: Nathalie Ginovart; Laurent Galineau; Matthaeus Willeit; Romina Mizrahi; Peter M Bloomfield; Philip Seeman; Sylvain Houle; Shitij Kapur; Alan A Wilson Journal: J Neurochem Date: 2006-04-05 Impact factor: 5.372
Authors: Oliver D Howes; Subrata K Bose; Federico Turkheimer; Isabel Valli; Alice Egerton; Lucia R Valmaggia; Robin M Murray; Philip McGuire Journal: Am J Psychiatry Date: 2011-07-18 Impact factor: 18.112
Authors: Ragy R Girgis; Mark Slifstein; Gary Brucato; Lawrence S Kegeles; Tiziano Colibazzi; Jeffrey A Lieberman; Anissa Abi-Dargham Journal: Mol Psychiatry Date: 2020-11-05 Impact factor: 13.437
Authors: Ana Weidenauer; Martin Bauer; Ulrich Sauerzopf; Lucie Bartova; Lukas Nics; Sarah Pfaff; Cecile Philippe; Neydher Berroterán-Infante; Verena Pichler; Bernhard M Meyer; Ulrich Rabl; Patrick Sezen; Paul Cumming; Thomas Stimpfl; Harald H Sitte; Rupert Lanzenberger; Nilufar Mossaheb; Alexander Zimprich; Pablo Rusjan; Georg Dorffner; Markus Mitterhauser; Marcus Hacker; Lukas Pezawas; Siegfried Kasper; Wolfgang Wadsak; Nicole Praschak-Rieder; Matthäus Willeit Journal: Transl Psychiatry Date: 2020-01-08 Impact factor: 6.222